These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 15996941

  • 1. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia.
    Raffoux E, Chaibi P, Dombret H, Degos L.
    Haematologica; 2005 Jul; 90(7):986-8. PubMed ID: 15996941
    [Abstract] [Full Text] [Related]

  • 2. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
    Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D, Neubauer A, Ruthardt M, Ottmann OG.
    Cancer; 2005 Dec 15; 104(12):2717-25. PubMed ID: 16294345
    [Abstract] [Full Text] [Related]

  • 3. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
    Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H, Gattermann N.
    Cancer; 2006 Jan 01; 106(1):112-9. PubMed ID: 16323176
    [Abstract] [Full Text] [Related]

  • 4. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
    Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, Germing U, Haas R, Gattermann N.
    Ann Hematol; 2005 Dec 01; 84 Suppl 1():61-6. PubMed ID: 16270213
    [Abstract] [Full Text] [Related]

  • 5. Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients.
    Bellos F, Mahlknecht U.
    Onkologie; 2008 Nov 01; 31(11):629-33. PubMed ID: 19145098
    [Abstract] [Full Text] [Related]

  • 6. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.
    Cimino G, Lo-Coco F, Fenu S, Travaglini L, Finolezzi E, Mancini M, Nanni M, Careddu A, Fazi F, Padula F, Fiorini R, Spiriti MA, Petti MC, Venditti A, Amadori S, Mandelli F, Pelicci PG, Nervi C.
    Cancer Res; 2006 Sep 01; 66(17):8903-11. PubMed ID: 16951208
    [Abstract] [Full Text] [Related]

  • 7. Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.
    Qi H, Ratnam M.
    Cancer Res; 2006 Jun 01; 66(11):5875-82. PubMed ID: 16740727
    [Abstract] [Full Text] [Related]

  • 8. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment.
    Fredly H, Reikvam H, Gjertsen BT, Bruserud O.
    Am J Hematol; 2012 Apr 01; 87(4):368-76. PubMed ID: 22374841
    [Abstract] [Full Text] [Related]

  • 9. DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy.
    Grishina O, Schmoor C, Döhner K, Hackanson B, Lubrich B, May AM, Cieslik C, Müller MJ, Lübbert M.
    BMC Cancer; 2015 May 26; 15():430. PubMed ID: 26008690
    [Abstract] [Full Text] [Related]

  • 10. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
    Pilatrino C, Cilloni D, Messa E, Morotti A, Giugliano E, Pautasso M, Familiari U, Cappia S, Pelicci PG, Lo Coco F, Saglio G, Guerrasio A.
    Cancer; 2005 Jul 01; 104(1):101-9. PubMed ID: 15895376
    [Abstract] [Full Text] [Related]

  • 11. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
    Trus MR, Yang L, Suarez Saiz F, Bordeleau L, Jurisica I, Minden MD.
    Leukemia; 2005 Jul 01; 19(7):1161-8. PubMed ID: 15902297
    [Abstract] [Full Text] [Related]

  • 12. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z, Cholovitsh M, Elezovitsh I, Vidovitsh A, Radoshevitsh-Radojkovitsh N, Boshkovitsh D, Novak A, Basara N.
    Srp Arh Celok Lek; 1995 Jul 01; 123(11-12):279-85. PubMed ID: 16296239
    [Abstract] [Full Text] [Related]

  • 13. [Combination of interferon-alpha and all-trans-retinoic acid as a treatment for maintaining remission in high-risk group patients with acute myeloid leukemia].
    Parovichnikova EN, Savchenko VG, Isaev VG, Demidova IA, Ol'shanskaia IuV, Lapin VA, Cherepanova VV, Rekhtman GB, Perekatova TN.
    Ter Arkh; 2001 Jul 01; 73(7):15-20. PubMed ID: 11523403
    [Abstract] [Full Text] [Related]

  • 14. [All-trans retinoic acid combined with low-dose cytosine arabinoside treatment for acute myelogenous leukemia with trilineage myelodysplasia--a case report].
    Maeda N, Satake S, Okada Y, Asahara S, Hasuike N, Tamura M, Takata M, Tasaka K, Okutani T, Maeda Y, Tomofuji Y, Chinzei T, Saigo K.
    Gan To Kagaku Ryoho; 2001 Mar 01; 28(3):407-10. PubMed ID: 11265415
    [Abstract] [Full Text] [Related]

  • 15. A pilot study of priming with granulocyte macrophage colony-stimulating factor plus all-trans retinoic acid combined with remission induction chemotherapy in patients with acute myeloid leukemia.
    Shin HJ, Chung JS, Choi YJ, Cho GJ.
    Am J Clin Oncol; 2009 Jun 01; 32(3):227-32. PubMed ID: 19433969
    [Abstract] [Full Text] [Related]

  • 16. All-trans retinoic acid in association with low dose cytosine arabinoside in the treatment of acute myeoid leukemia in elderly patients.
    Di Febo A, Laurenti L, Falcucci P, Tosti ME, Fianchi L, Pagano L, Leone G.
    Am J Ther; 2007 Jun 01; 14(4):351-5. PubMed ID: 17667210
    [Abstract] [Full Text] [Related]

  • 17. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate.
    Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR.
    Leukemia; 2009 Apr 01; 23(4):641-8. PubMed ID: 19151770
    [Abstract] [Full Text] [Related]

  • 18. Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.
    Lübbert M, Grishina O, Schmoor C, Schlenk RF, Jost E, Crysandt M, Heuser M, Thol F, Salih HR, Schittenhelm MM, Germing U, Kuendgen A, Götze KS, Lindemann HW, Müller-Tidow C, Heil G, Scholl S, Bug G, Schwaenen C, Giagounidis A, Neubauer A, Krauter J, Brugger W, De Wit M, Wäsch R, Becker H, May AM, Duyster J, Döhner K, Ganser A, Hackanson B, Döhner H, DECIDER Study Team.
    J Clin Oncol; 2020 Jan 20; 38(3):257-270. PubMed ID: 31794324
    [Abstract] [Full Text] [Related]

  • 19. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells.
    Reikvam H, Hovland R, Forthun RB, Erdal S, Gjertsen BT, Fredly H, Bruserud Ø.
    BMC Cancer; 2017 Sep 06; 17(1):630. PubMed ID: 28877686
    [Abstract] [Full Text] [Related]

  • 20. Valproic acid for the treatment of myeloid malignancies.
    Kuendgen A, Gattermann N.
    Cancer; 2007 Sep 01; 110(5):943-54. PubMed ID: 17647267
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.